Phase 2a ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion

NCT ID: NCT02465216

Last Updated: 2019-03-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-06-30
• Study Completion Date: 2017-01-31

Brief Summary

The purpose of this study is to evaluate the safety and immunogenicity of ID93 + GLA-SE vaccine when administered to adult pulmonary Tuberculosis (TB) patients, following successful completion of TB treatment with confirmed bacteriologic cure, in preparation for a future Phase 2b prevention of TB recurrence trial in the same population.

Conditions

Pulmonary Tuberculosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: TRIPLE

Study Groups

2 mcg ID93 + 2 mcg GLA-SE Vaccine

Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. Low dose of antigen and low dose of adjuvant.

Group Type: EXPERIMENTAL

ID93 + GLA-SE

Intervention Type: BIOLOGICAL

ID93 + GLA-SE

10 mcg ID93 + 2 mcg GLA-SE Vaccine

Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. High dose of antigen and low dose of adjuvant.

Group Type: EXPERIMENTAL

ID93 + GLA-SE

Intervention Type: BIOLOGICAL

ID93 + GLA-SE

2 mcg ID93 + 5 mcg GLA-SE Vaccine

Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. Low dose of antigen and high dose of adjuvant. Placebo injection at Day 28 to maintain blind with the 3 dose arm.

Group Type: EXPERIMENTAL

ID93 + GLA-SE

Intervention Type: BIOLOGICAL

ID93 + GLA-SE

Placebo

Two intramuscular injections of normal saline at Days 0 and 56, or Days 0, 28, and 56.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Placebo

2 mcg ID93 + 5 mcg GLA-SE Vaccine 3 doses

Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 56. Low dose of antigen and high dose of adjuvant.

Group Type: EXPERIMENTAL

ID93 + GLA-SE

Intervention Type: BIOLOGICAL

ID93 + GLA-SE

Interventions

Placebo

Placebo

Intervention Type: OTHER

ID93 + GLA-SE

ID93 + GLA-SE

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Males and females 18 to 60 years of age.

2. Subjects must have been successfully treated, i.e., completed the scheduled course of TB treatment as per the prevailing South African national guidelines, for MTB culture-confirmed, drug sensitive pulmonary TB, as evidenced by a record of positive liquid MTB culture with formal drug sensitivity testing (DST) and/or by Xpert MTB/RIF test at baseline.

3. Must have two separate samples showing bacteriologic confirmation of cure - defined in the first instance as Xpert MTB/RIF test negative, or, if Xpert MTB/RIF positive, as MTB liquid culture negative - on two successive occasions at least 30 days apart. Subjects who are sputum unproductive will be deemed Xpert MTB/RIF and MTB liquid culture negative.

4. Female subjects of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test on the day of each study injection, must not be breast-feeding, and be willing to avoid pregnancy for 3 months following first study injection. Women physically capable of pregnancy (not sterilized and still menstruating or within 1 year of the last menses if menopausal) in sexual relationships with men must use an acceptable method of avoiding pregnancy during this period. Acceptable methods of avoiding pregnancy include a sterile sexual partner, sexual abstinence (not engaging in sexual intercourse), hormonal contraceptives (oral, injection, transdermal patch, or implant), vaginal ring, intrauterine device (IUD), or the combination of a condom or diaphragm with spermicide gel.

5. The following screening laboratory values must be within the laboratory reference range or, if abnormal, deemed not clinically significant and less than Grade 2 severity on the FDA Toxicity Scale, as determined by the PI and LMM or Sponsor Medical Advisor: ALT, AST, total bilirubin, creatinine, total WBC count, hemoglobin, and platelet count.

6. The HIV 1/2 antibody serology tests must be negative.

7. Must give informed consent, be able and willing to make all evaluation visits, be reachable by telephone or personal contact by the study site personnel, and be willing to remain in the study area for the duration of the trial.

Exclusion Criteria

1. TB treatment failure, as evidenced by clinical diagnosis or a positive MTB liquid culture at month 4 or 5 after starting treatment. A positive MTB liquid culture at, or after, end of treatment would exclude subjects from receiving further study injections.

2. Previous course of TB treatment completed within 5 calendar years prior to obtaining baseline diagnostic sputum samples.

3. Receipt of any investigational products or investigational drug in the past 6 months or investigational vaccine ever.

4. Treatment with immunosuppressive drugs (e.g., oral or injected steroids, such as prednisone; high dose inhaled steroids) in the past 6 months. Topical steroids would be allowable.

5. Received incomplete or investigational, or non-standard TB drug regimen, other than the prevailing current South African national guideline as reference standard, or poor adherence to TB treatment regimen.

6. Diagnosed with rifampicin-resistant MTB strain (by Xpert MTB/RIF and/or culture and formal DST).

7. History of autoimmune disease or other causes of immunosuppressive states.

8. History or evidence of any acute or chronic illness (including diabetes mellitus, asthma), medical or surgical condition, or chronic heavy ethanol or drug use, or use of medication that, in the opinion of the Principal Investigator, may interfere with the evaluation of the safety or immunogenicity of the vaccine.

9. Subjects with a history of previous anaphylaxis or severe allergic reaction to vaccines, eggs, or unknown allergens.

10. Subjects who are unlikely to cooperate with the requirements of the study protocol.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Wellcome Trust

OTHER

Sponsor Role: collaborator

South African Tuberculosis Vaccine Initiative

OTHER

Sponsor Role: collaborator

Access to Advanced Health Institute (AAHI)

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Mark Hatherill, MD

Role: PRINCIPAL_INVESTIGATOR

South African Tuberculosis Vaccine Initiative

Locations

TASK Applied Sciences

Cape Town, , South Africa

Desmond Tutu HIV Centre (DTHC)

Cape Town, , South Africa

South African Tuberculosis Vaccine Initiative (SATVI)

Worcester, , South Africa

Countries

South Africa

References

Day TA, Penn-Nicholson A, Luabeya AKK, Fiore-Gartland A, Du Plessis N, Loxton AG, Vergara J, Rolf TA, Reid TD, Toefy A, Shenje J, Geldenhuys H, Tameris M, Mabwe S, Bilek N, Bekker LG, Diacon A, Walzl G, Ashman J, Frevol A, Sagawa ZK, Lindestam Arlehamn C, Sette A, Reed SG, Coler RN, Scriba TJ, Hatherill M; TBVPX-203 study team. Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet Respir Med. 2021 Apr;9(4):373-386. doi: 10.1016/S2213-2600(20)30319-2. Epub 2020 Dec 8.

Reference Type: DERIVED

PMID: 33306991 (View on PubMed)

Other Identifiers

IDRI-TBVPX-203

Identifier Type: -

Identifier Source: org_study_id